Brookfield Asst Financials

BAM

FY2025 annual

Revenue $4.8B +21.0% YoY

Net Income $2.4B +13.8% YoY

EPS (Diluted) Not reported for FY2025

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Brookfield Asst (BAM) reported $4.8B in revenue for fiscal year 2025, up 21.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BAM FY2025 2026-08-10

Cash-backed earnings and distribution-heavy capital returns define a business still digesting a much larger balance sheet.

Assets expanded more than fivefold from FY2023 to FY2025, but net income stayed in a tight band, pulling ROA down to 14.1%. The more revealing shift is that revenue and operating cash flow both reached their three-year highs in FY2025, suggesting the larger platform is starting to earn into that bigger asset base rather than merely carrying it.

Operating cash flow still trailed profit, but the gap narrowed by FY2025 as cash generation reached $2.1B against net income of $2.4B. That improves earnings quality: recent profit looks more convertible to cash, not just favorable on paper.

Dividends paid topped operating cash flow in all three years, including $2.8B versus $2.1B in FY2025, so shareholder payouts were not funded solely by that year's operations. Even so, cash balances rose to $1.6B and debt-to-equity moved up to 0.8x, a sign that capital returns are being managed alongside a less conservative balance-sheet posture.

Financial Health Signals

Financial health score not available

Brookfield Asst does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/5

Brookfield Asst passes 3 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 2 of 4 profitability signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

0.88x

For every $1 of reported earnings, Brookfield Asst generates $0.88 in operating cash flow ($2.1B OCF vs $2.4B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.8B

YoY+21.0%

Brookfield Asst generated $4.8B in revenue in fiscal year 2025. This represents an increase of 21.0% from the prior year.

Net Income

$2.4B

YoY+13.8%

Brookfield Asst reported $2.4B in net income in fiscal year 2025. This represents an increase of 13.8% from the prior year.

EBITDA

Not reported for fiscal year 2025.

EPS (Diluted)

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$1.6B

YoY+291.8%

Brookfield Asst held $1.6B in cash as of fiscal year 2025; long-term debt is not reported for that period.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Shares Outstanding

Not reported for fiscal year 2025.

Margins & Returns

Net Margin

49.8%

YoY-3.2pp

Brookfield Asst's net profit margin was 49.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 3.2 percentage points from the prior year.

Return on Equity

26.9%

YoY+2.8pp

Brookfield Asst's ROE was 26.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2.8 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Capital Allocation

Share Buybacks

$412.0M

Brookfield Asst spent $412.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

R&D Spending

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

BAM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BAM annual income statement

Metric	TTM	FY25	FY24	FY23
Revenue	$5.7B	$4.8B+21.0%	$4.0B-2.0%	$4.1B
SG&A Expenses	$79.0M	$56.0M-12.5%	$64.0M+14.3%	$56.0M
Interest Expense	$143.0M	$87.0M+295.5%	$22.0M+144.4%	$9.0M
Income Tax	$649.0M	$527.0M+20.3%	$438.0M+5.0%	$417.0M
Net Income	$3.1B	$2.4B+13.8%	$2.1B-1.4%	$2.1B
EPS (Diluted)	—	N/A	N/A	$1.13

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$1.8B+31.0%	$1.3B-4.0%	$1.4B+11.3%	$1.3B+14.9%	$1.1B+0.8%	$1.1B+1.7%	$1.1B-4.8%	$1.1B
SG&A Expenses	$25.0M+13.6%	$22.0M+144.4%	$9.0M-60.9%	$23.0M+27.8%	$18.0M+200.0%	$6.0M-72.7%	$22.0M+10.0%	$20.0M
Interest Expense	$53.0M+43.2%	$37.0M+12.1%	$33.0M+65.0%	$20.0M-35.5%	$31.0M+933.3%	$3.0M-57.1%	$7.0M-12.5%	$8.0M
Income Tax	$162.0M+47.3%	$110.0M-63.2%	$299.0M+283.3%	$78.0M+4.0%	$75.0M0.0%	$75.0M-41.9%	$129.0M+34.4%	$96.0M
Net Income	$1.2B+100.0%	$586.0M-4.7%	$615.0M-11.1%	$692.0M+18.5%	$584.0M+15.2%	$507.0M-25.4%	$680.0M+26.6%	$537.0M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Operating Income.

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

BAM Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BAM annual balance sheet

Metric	FY25	FY24	FY23
Total Assets	$17.0B+20.4%	$14.2B+341.7%	$3.2B
Cash & Equivalents	$1.6B+291.8%	$404.0M+4388.9%	$9.0M
Accounts Receivable	$106.0M-52.9%	$225.0M	N/A
Goodwill	$236.0M-6.0%	$251.0M	N/A
Total Liabilities	$6.7B+127.1%	$3.0B+164.8%	$1.1B
Total Equity	$8.9B+1.8%	$8.8B+321.6%	$2.1B
Retained Earnings	-$851.0M-74.4%	-$488.0M-1294.3%	-$35.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$20.1B+11.9%	$17.9B+5.2%	$17.0B+3.2%	$16.5B+2.3%	$16.1B+7.9%	$15.0B+5.7%	$14.2B	N/A
Cash & Equivalents	$1.5B+43.8%	$1.0B-34.0%	$1.6B+49.1%	$1.1B+121.2%	$480.0M+44.6%	$332.0M-17.8%	$404.0M-55.3%	$903.0M
Accounts Receivable	N/A	N/A	$106.0M	N/A	N/A	N/A	$225.0M	N/A
Goodwill	$236.0M0.0%	$236.0M0.0%	$236.0M	N/A	N/A	N/A	$251.0M	N/A
Total Liabilities	$8.2B+22.5%	$6.7B-0.5%	$6.7B+15.2%	$5.8B+14.4%	$5.1B+25.5%	$4.1B+37.3%	$3.0B	N/A
Long-Term Debt	$4.1B+38.4%	$3.0B	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.2B+7.0%	$8.6B-3.7%	$8.9B+5.3%	$8.5B-0.1%	$8.5B-0.2%	$8.5B-3.0%	$8.8B-2.8%	$9.0B
Retained Earnings	-$950.0M+9.3%	-$1.0B-23.0%	-$851.0M-20.9%	-$704.0M+1.5%	-$715.0M-15.9%	-$617.0M-26.4%	-$488.0M	N/A

Not reported in any period shown, so not listed: Current Assets, Inventory, Current Liabilities, Long-Term Debt.

BAM Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BAM annual cash flow statement

Metric	TTM	FY25	FY24	FY23
Operating Cash Flow	$2.3B	$2.1B+30.3%	$1.6B+12.0%	$1.4B
Investing Cash Flow	-$232.0M	-$339.0M+80.6%	-$1.7B-267.2%	-$475.0M
Financing Cash Flow	-$1.1B	-$590.0M+72.2%	-$2.1B-15.0%	-$1.8B
Dividends Paid	$3.0B	$2.8B+13.7%	$2.5B+17.9%	$2.1B
Share Buybacks	$872.0M	$412.0M	$0-100.0%	$319.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$545.0M+61.2%	$338.0M-52.1%	$706.0M-5.2%	$745.0M+40.8%	$529.0M+364.0%	$114.0M-16.2%	$136.0M-76.0%	$567.0M
Investing Cash Flow	-$308.0M-292.5%	$160.0M+310.5%	-$76.0M-850.0%	-$8.0M+98.4%	-$490.0M-308.5%	$235.0M+535.1%	$37.0M+102.8%	-$1.3B
Financing Cash Flow	$173.0M+117.6%	-$983.0M-810.2%	-$108.0M+32.9%	-$161.0M-249.1%	$108.0M+125.6%	-$422.0M+36.0%	-$659.0M-137.9%	-$277.0M
Dividends Paid	$802.0M-0.9%	$809.0M+15.1%	$703.0M-0.4%	$706.0M+0.6%	$702.0M-0.7%	$707.0M+14.2%	$619.0M-0.2%	$620.0M
Share Buybacks	$200.0M-46.8%	$376.0M+65.6%	$227.0M+229.0%	$69.0M	$0-100.0%	$116.0M	$0	$0

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow.

BAM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BAM annual financial ratios

Metric	FY25	FY24	FY23
Net Margin	49.8%-3.2pp	53.0%+0.3pp	52.6%
Return on Equity	26.9%+2.8pp	24.1%-78.9pp	102.9%
Return on Assets	14.1%-0.8pp	14.9%-51.8pp	66.7%
Debt-to-Equity	0.76+0.4x	0.34-0.2x	0.54

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Net Margin	66.9%+23.1pp	43.8%-0.3pp	44.1%-11.1pp	55.3%+1.7pp	53.6%+6.7pp	46.9%-17.1pp	64.0%+15.9pp	48.1%
Return on Equity	12.8%+5.9pp	6.8%-0.1pp	6.9%-1.3pp	8.2%+1.3pp	6.9%+0.9pp	6.0%-1.8pp	7.8%+1.8pp	6.0%
Return on Assets	5.8%+2.6pp	3.3%-0.3pp	3.6%-0.6pp	4.2%+0.6pp	3.6%+0.2pp	3.4%-1.4pp	4.8%	N/A
Debt-to-Equity	0.44+0.1x	0.34-0.4x	0.76+0.1x	0.69+0.1x	0.60+0.1x	0.48+0.1x	0.34	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Current Ratio, FCF Margin.

Similar Companies

Brookfield Corporation BN

$93.1B

Apollo Global Mgmt Inc APO

$78.4B

Kkr & Co Inc KKR

$97.4B

Ares Management Corporation ARES

$31.9B

Blackrock BLK

$179.1B

Where Brookfield Asst Ranks

Frequently Asked Questions

What is Brookfield Asst's annual revenue?

Brookfield Asst (BAM) reported $4.8B in total revenue for fiscal year 2025. This represents a 21.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Brookfield Asst's revenue growing?

Brookfield Asst (BAM) revenue grew by 21.0% year-over-year, from $4.0B to $4.8B in fiscal year 2025.

Is Brookfield Asst profitable?

Yes, Brookfield Asst (BAM) reported a net income of $2.4B in fiscal year 2025, with a net profit margin of 49.8%.

What is Brookfield Asst's net profit margin?

Brookfield Asst (BAM) had a net profit margin of 49.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Brookfield Asst's return on equity (ROE)?

Brookfield Asst (BAM) has a return on equity of 26.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Brookfield Asst's operating cash flow?

Brookfield Asst (BAM) generated $2.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Brookfield Asst's total assets?

Brookfield Asst (BAM) had $17.0B in total assets as of fiscal year 2025, including both current and long-term assets.

Does Brookfield Asst buy back shares?

Yes, Brookfield Asst (BAM) spent $412.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

What is Brookfield Asst's debt-to-equity ratio?

Brookfield Asst (BAM) had a debt-to-equity ratio of 0.76 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Brookfield Asst's return on assets (ROA)?

Brookfield Asst (BAM) had a return on assets of 14.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Brookfield Asst's Piotroski F-Score?

Brookfield Asst (BAM) has a Piotroski F-Score of 3 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Brookfield Asst's earnings high quality?

Brookfield Asst (BAM) has an earnings quality ratio of 0.88x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.